Posted by Michael Wonder on 29 Apr 2020
Novartis Cosentyx gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
29 April 2020 - Cosentyx is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis, which forms part of the axial spondyloarthritis disease spectrum.
Novartis today announced the European Commission has approved Cosentyx (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis.
“This approval of Cosentyx for non-radiographic axial spondyloarthritis means clinicians across Europe now have an effective new treatment option to help patients gain relief from the burden of this painful, debilitating disease and achieve a better quality of life both at home and at work,” said Atul Deodhar, MD, Professor of Medicine and Medical Director of Rheumatology Clinics at Oregon Health & Science University, USA, and an investigator in the PREVENT clinical trial.
